This Article Full Text Full Text (PDF) All Versions of this Article: 39/2/289    most recent STROKEAHA.107.511485v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Singhal, A. B. Articles by Lo, E. H. Search for Related Content PubMed PubMed Citation Articles by Singhal, A. B. Articles by Lo, E. H. Pubmed/NCBI databases Medline Plus Health Information Stroke Related Collections Other Stroke Treatment - Medical

(Stroke. 2008;39:289.)
© 2008 American Heart Association, Inc.

Advances in Stroke 2007

Advances in Emerging Nondrug Therapies for Acute Stroke 2007

From the Neuroprotection Research Laboratory, Program in Neuroscience, Harvard Medical School, and Department of Neurology, Massachusetts General Hospital, Boston, Mass.

Correspondence to Aneesh B. Singhal, J. Philip Kistler Stroke Research Center, Massachusetts General Hospital, 175 Cambridge Street, Suite 300, Boston, MA 02114. E-mail asinghal@partners.org

Key Words: acute stroke • non-drug therapies • therapy

An extract of the first 250 words of the full text is provided, because this article has no abstract.

Numerous clinical trials of thrombolytic and neuroprotective drugs for stroke have been conducted over the last 2 decades. The NINDS trial of intravenous tissue plasminogen activator remains the most notable success. Intra-arterial thrombolysis appears promising, but in the absence of phase III clinical trial data, this approach remains investigational. Numerous pharmaceutical drugs targeting 1 or more cell death pathways have failed to show efficacy. Despite failure, these prior attempts have provided insights regarding critical issues such as proper clinical trial design and the need for more rigorous preclinical drug testing in order to improve the translational leap from bench to bedside.

More recently, accumulating data suggest that "non-drug" approaches toward stroke therapy might also provide new opportunities in addition to more traditional pharmaceutical therapies. As testimony to the growing importance of these alternate and sometimes complementary methods, there has been a proliferation of device trials, and the NINDS, through its key ‘Specialized Program of Translational Research in Acute Stroke’ [SPOTRIAS] initiative,¹ has funded trials of therapeutic hypothermia, caffeinol, and normobaric hyperoxia, among others. Although this brief survey focuses on emerging gas and device therapies for ischemic stroke, it should be noted that several other ‘non-drug’ approaches, including physiological strategies (eg, hypothermia, glucose regulation), and natural agents (eg, albumin, magnesium), continue to be tested in ongoing trials.

Gases

Increasing brain tissue oxygenation has long been considered a logical stroke treatment strategy. Although initial efforts using hyperbaric oxygen (HBO) chambers were unsuccessful, the realization that early trials had numerous methodological shortcomings has led . . . [Full Text of this Article]